The United States Justice Department has declared its intention to scrutinise the role of private equity firms in instances of healthcare fraud, as per the head of the Civil Division. An increasing number of cases have brought attention to the significant and growing influence of these firms within the healthcare field and generated concerns regarding their subsequent impact on healthcare billings.
The Civil Division’s leading authority, Brian Boynton, voiced these concerns during a noteworthy legal conference in Washington. Boynton pointed out that civil investigators have observed the heightened incidences of private equity and venture capital firms, as well as other investment sources, manipulating the conduct of medical providers. These actions range from providing explicit directions to setting revenue goals and other clandestine benchmarks designed to prioritize reimbursement.
While Boynton did acknowledge that the involvement of private equity and other third-parties in the healthcare industry is not inherently an issue, he highlighted the potential risks of these entities “undermining medical judgment”, leading to healthcare firms submitting fraudulent claims to the government. The Justice Department, Boynton stressed, will not shy away from taking strict action against private equity firms that play a role in defrauding the government.
This discussion was part of an annual conference focused on False Claims Act practitioners, which was organized by the Federal Bar Association. In coming years it will be crucial to monitor how these increased scrutiny measures impact the private equity sector, particularly within healthcare.
For additional information, please visit the original article here.